Despite high borrowing costs and extended hold times in 2024, dealmaking roared ahead for healthcare private equity with a heavy focus on biopharma North American and European deal activity surged in 2024, offsetting a 49% decline in deal volume in Asia-Pacific since 2023 NEW YORK, Jan….
